• 作者：E. G&#243 ; mez-de la Fuente^a ; ^{egomezf@fhalcorcon.es} ; L.B. Villal&#243 ; n^b ; L. Calzado-Villarreal^a ; F. Pinedo-Moraleda^c ; J.L. L&#243 ; pez-Estebaranz^a
• 关键词：Linfoma B de la zona marginal ; Linfoma cutá ; neo de la zona marginal ; Linfoma esplé ; nico ; Rituximab
• 刊名：Actas Dermo-Sifiliogr谩ficas
• 出版年：2012
• 期刊代码：pca35_00017310
• 类别：med
• 出版时间：June, 2012
• 卷：103
• 期：5
• 页码：427-431
• 文件大小：1790 K

Marginal zone B-cell lymphoma (MZL) is subclassified into extranodal MZL of mucosa-associated lymphoid tissue (including cutaneous lymphomas), splenic MZL, and nodal MZL. We report the case of a 68-year-old man with erythematous-violaceous plaques and nodules. Skin biopsy showed an epidermotropic lymphocytic infiltration and cytology and immunohistochemistry were consistent with MZL. The workup revealed disease in the peripheral blood and bone marrow and massive splenomegaly. Splenectomy confirmed the diagnosis of splenic MZL and led to resolution of the skin lesions. Cutaneous recurrence was treated successfully with chemotherapy and rituximab but caused fatal hepatitis due to hepatitis B virus reactivation. Skin involvement by splenic MZL is uncommon; this form of the disease can present epidermotropism, a very rare finding in primary cutaneous MZL. Treatment consists of splenectomy, which may be associated with chemotherapy and/or rituximab; this treatment may lead to reactivation of latent hepatitis B infection and screening for hepatitis should therefore be performed prior to starting therapy.